

Post-EHA 2026 Multiple Myeloma Highlights

Webinar Series by VJHemOnc

30 June 2026 | 12:00–14:00 CDT / 18:00–20:00 BST / 19:00–21:00 CEST

VJHEM Onc™



Agenda

Chair: Karthik Ramasamy | **Moderators:** Cyrille Touzeau & Nisha Joseph

		Time (BST)
Welcome and introductions	Karthik Ramasamy	18:00–18:05
Session 1: Latest in targeted immune modulation and cellular therapy		18:05–18:25
Arlocabtagene autoleucel, A GPRC5D-targeted CAR T-cell therapy for patients with relapsed/refractory multiple myeloma: Updated Phase 1 safety and efficacy results in patients with 1–3 prior regimens (Abstract S200)	Susan Bal	
CB-011, an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking, for patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE Phase 1 trial) (Abstract S201)	Binod Dhakal	
Safety and efficacy of iberdomide-based quadruplet for patients with newly diagnosed multiple myeloma: The IDEAL Phase I/II trial results (Abstract S199)	Prashant Kapoor	
Updated results of a phase 1 first-in-human study of cemsidomide, a novel MONODAC® degrader, with dexamethasone (DEX) in patients with RRMM (Abstract PF763)	Binod Dhakal	
Panel discussion		18:25–18:40
Session 2: Advances in T-cell engager monotherapy in smoldering myeloma & amyloidosis		18:40–19:00
Phase 3 randomized trial of anselamimab demonstrates improvement in all-cause mortality in K light-chain amyloidosis (Abstract S206)	Ashutosh Wechalekar	
Initial efficacy and safety data from the Phase 1/2 LINKER-AL2 study of linvoseltamab (linvo) monotherapy in patients with relapsed or refractory (RR) systemic light chain (AL) amyloidosis (Abstract S208)	Ashutosh Wechalekar	
Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the Phase 2 ERASMM (EMN34) study (Abstract S205)	Claudio Cerchione	
Teclistamab improves depth of response and PFS versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: results from the Phase 2 IMMUNOPRISM trial (Abstract LB5008)	Omar Nadeen	
Panel discussion		19:00–19:15

Session 3: Recent progress in T-cell engager combination approaches in NDMM and RRMM		19:15–19:40
Teclistamab (tec) +/- lenalidomide (len) versus len alone as maintenance therapy post-transplant in newly diagnosed multiple myeloma (NDMM): Updated safety run-in (SRI) results from EMN30/MAJESTEC-4 (Abstract S197)	Niels van de Donk	
High MRD negativity rates and prolonged PFS with belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone in transplant ineligible newly-diagnosed myeloma: Results of the BELA-DRD study (Abstract S204)	Evangelos Terpos	
Phase 3, randomized study of talquetamab (Tal) plus daratumumab (Dara) ± pomalidomide (Pom) vs dara plus pom and dexamethasone (DPD) in relapsed/refractory multiple myeloma (RRMM): MONUMENTAL-3 (Abstract S100)	Meral Beksaç	
MAJESTEC-9: A Phase 3 study of teclistamab monotherapy vs pomalidomide/bortezomib/dexamethasone or carfilzomib/dexamethasone (PVD/KD) in patients (PTS) with relapsed refractory multiple myeloma (RRMM) (Abstract S195)	Roberto Mina	
Teclistamab plus daratumumab (TEC-DARA) in patients (PTS) with relapsed refractory multiple myeloma (RRMM): Analysis of MAJESTEC-3 based on cytogenetic and functional risk (Abstract S198)	Rahul Banerjee	
Panel discussion		19:4019:55
Conclusions and webinar close	Karthik Ramasamy	19:55–20:00